EUCTR2022-002245-18-BE进行中（未招募）1 期
A Phase I/Ib Dose Escalation and Cohort Expansion Study of OMX-0407 a Salt-inducible Kinase inhibitor in patients with previously treated unresectable solid tumours - OMX-0407 Phase I/Ib Study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 208
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •General Inclusion Criteria for both Dose Escalation and Cohort Expansion Phases:
- •A subject must meet all the following criteria to be eligible to participate in this study.
- •1.Age =18 years (=16 years for the AS expansion cohort) and and willing to provide informed consent for the study.
- •2.Cytological or pathological confirmation of advanced cancer.
- •3.Subjects will be required to provide either archival tumour material or be willing to undergo a core biopsy to provide tumour material during screening.
- •4.Subjects should have completed or be unsuitable for licensed therapies for their primary cancer unless such therapies are not available according to local practice – for example not reimbursed or included in treatment guidelines. All subjects must have received at least one previous line of systemic therapy for the tumour type under investigation. Subjects who have declined treatment or according to their treating physician are unsuitable for an existing licensed therapy are eligible for the study.
- •5.ECOG Performance status 0, 1 or 2. Subjects treated in the cohort expansion phase of the study should have an ECOG Performance status of 0 or 1.
- •6.Able to swallow oral medication with no existing evidence of underlying gastrointestinal malabsorption or abnormal gastrointestinal transit.
- •7.For female subjects and male partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g., oral contraceptive and condom, intra-uterine device, and condom) while on study and for 30 days after the last study treatment. For male subjects or female partners of childbearing potential, willingness and able to use two forms of highly effective contraception methods (e.g., oral contraceptive and condom, intra-uterine device, and condom) while on study and for 3 months after the last study treatment.
- •Women who last experienced menses more than one year previously or who have undergone bilateral ovariectomy, hysterectomy or tubal ligation which is documented in their medical notes do not require to use contraception during or after treatment with OMX-0407.
- •Male subjects who have previously undergone vasectomy are not required to use contraception.
- •8.All toxicity from previous anti-cancer therapy including radiotherapy must have recovered to either Grade I or stable Grade II (CTCAE v5).
- •9.Subjects should have at least evaluable tumour by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria. Subjects treated in the Cohort Expansion phases of the study should have measurable disease.
- •Additional Inclusion Criteria For Cohort Expansion Phase: ccRCC
- •1.Prior histological confirmation of clear cell renal cell carcinoma. In the case of mixed histology in order to be eligible at least 70% of reviewed tumour should be of clear cell histology.
- •2.Subjects with known renal vascular involvement by tumour should be on stable anticoagulation at the start of treatment with OMX-0407. Tumour/skin biopsies should be performed prior to the onset of anticoagulation.
- •3.Previous treatment must include PD-1 blockade and VEGFR inhibiton
- •Additional Inclusion Criteria for Cohort Expansion Phase: sqNSCLC
- •1.Prior histological confirmation of sqNSCLC. Subjects with mixed histology tumours must have predominantly squamous histology.
- •2.Previous treatment must include PD-1 blockade and platinum chemotherapy.
- •3.Patients with known oncogenic drivers including EGFR mutations ALK genomic rearrangements mus
排除标准
- •General Exclusion Criteria for both Dose Escalation and Cohort Expansion Phases
- •1.Untreated CNS metastases. Subjects with CNS metastases that have completed treatment at least two weeks previously and have either an unchanging or no neurological deficit whilst not receiving corticosteroid therapy are eligible. Subjects with known CNS metastases must have received CNS directed therapy and not systemic therapy alone to be eligible for the study.
- •2.Either Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) > 2.5 upper limit of normal (ULN) unless in the presence of hepatic metastases when AST or ALT as high as 5 ULN is acceptable. Serum bilirubin > 1.5 ULN unless in the presence of hepatic metastases when serum bilirubin as high as 3 x ULN is acceptable. Subjects with isolated increases in alkaline phosphatase (ALK) are eligible for the study.
- •3.Prothrombin Time or equivalent such as international normalized ratio (INR) or the Quick test > 1.5 ULN.
- •4.Activated Partial Thromboplastin Time (PTT) > 1.5 ULN.
- •5.Chronic anticoagulant therapy that cannot be discontinued for tumour biopsy if necessary.
- •6.Previous biological or unlicensed anticancer therapy within five half-lives or thirty days of treatment with OMX-0407 – whichever is shortest.
- •7.Prior cytotoxic chemotherapy in the preceding three weeks.
- •8.Persistent fever or other signs of uncontrolled infection.
- •9.Creatinine clearance by Cockcroft-Gault formula or local equivalent < 30 ml/min.
- •10.Allergy to OMX-0407 or any of its excipients.
- •11.Personal or family history of long QT syndrome or sudden death.
- •12.Family or personal history of ventricular arrythmia. Known untreated aberrant preexcitation pathways such as Wolf-Parkinson-White syndrome. Ongoing atrial fibrillation unless ventricular rate controlled by medical therapy.
- •13.Unstable hypertension requiring changes in antihypertensive medication within the preceding three months, Myocardial Infarction or Cerebrovascular accident within the preceding three months. Cardiac failure New York Heart Association (NYHA) Grade III or IV.
- •14.Abnormal ECHO according to investigational site criteria including a normal Ejection Fraction.
- •15.QTc interval after Fridericia correction of greater than 450 ms (man) or 460 ms (woman) (mean of three readings performed at least five minutes apart).
- •16.Second degree Atrioventricular block or cardiac pacemaker.
- •17.Subject must have fully recovered from major surgery such as thoracotomy. Open biopsy or insertion of a venous access device does not constitute major surgery.
- •18.Known active Hepatitis B (HBV) or C (HCV) including subjects receiving antiviral therapy. Subjects with a history of hepatitis are eligible for the study if they are positive for anti-HBs or do not have detectable HCV mRNA at least six weeks from completing antiviral therapy.
- •19.Ongoing disabling systemic disease such chronic obstructive pulmonary disease (COPD) or depression or other psychiatric illnesses which may reduce study compliance.
- •20.Ongoing drug dependence or parenteral substance abuse.
- •21.Concurrent use of medications at risk of Torsade de Pointes under normal clinical usage.
- •22.Live vaccinations in the preceding four weeks.
- •23.Subjects who have received treatment for another malignancy in the preceding three years other than squamous cell or basal cell carcinoma of the skin, Carcinoma In Situ of the uterine cervix, Ductal Carcinoma In Situ of the breast, non-muscle invasive carcinoma of t
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid TumorsSolid tumorsMedDRA version: 19.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001359-36-FRBristol-Myers Squibb International Corporation171
进行中（未招募）
1 期
A Phase 1/2 Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid TumorsSolid tumorsMedDRA version: 19.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001359-36-ITBristol-Myers Squibb International Corporation171
已完成
1 期
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumorseoplasms by SiteJPRN-jRCT2080223834Bristol-Myers Squibb K.K.1,000
进行中（未招募）
1 期
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC or Hepatocellular Carcinoma.Advanced Refractory SolidTumours (Phase 1b) and in Recurrent or RefractoryNon–Small Cell Lung Cancer or Hepatocellular Carcinoma, (Phase 2)EUCTR2015-002093-20-DEEli Lilly and Company75
招募中
不适用
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton*s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell MalignanciesNL-OMON54003urix Therapeutics, Inc40